

Supplemental Digital Content 1. Characteristics of 255 HIV/HCV coinfectd patients, who underwent a liver biopsy.

	All patients
No. HIV-1 patients *	255
Gender (male) *	194 (76.07%)
Age (years) #	39.52 (37.1; 43.6)
Epidemiological history	
Injection drug users *	219 (85.8%)
Years since HCV infection #	21.4 (17.3; 24.5)
High alcohol intake *	135 (53.4%)
CDC category C *	74 (29.02%)
Antiretroviral therapy *	
Non treated	39 (15.3%)
PI-based	60 (23.5%)
NNRTI-based	122 (47.8%)
3 NRTI-based	34 (13.3%)
Metavir fibrosis stage *	
No fibrosis (F0)	24 (9.4%)
Portal fibrosis (F1)	95 (37.2%)
Periportal fibrosis (F2)	68 (26.7%)
Bridging fibrosis (F3)	43 (16.9%)
Cirrhosis (F4)	25 (9.8%)
Metavir activity grade (no.=254)*	
No activity (A0)	6 (2.3%)
Mild activity (A1)	108 (42.5%)
Moderate activity (A2)	104 (40.9%)
Severe activity (A≥3)	36 (14.2%)
HIV markers	
Nadir CD4+ T-cells #	203 (88; 329)
CD4+ T-cells/μL #	483 (360; 680)
HIV-RNA < 50 cp/mL *	180 (70.58)
HCV markers *	
HCV-genotype 1	154 (61.4%)
HCV RNA >500,000 UI/mL	177 (73.1%)
Biochemical parameters #	
Glucose (mg/dL)	86 (77; 94)
ALT (UI/dL)	74 (47; 114.2)
AST (UI/dL)	54 (35.7; 82.2)
GGT (UI/dL)	92 (52; 182.2)
AST/ALT	0.78 (0.62; 1.00)
Cholesterol	175 (146; 202)

*Absolute number (percentage). #Median (percentile 25; percentile 75).

Abbreviations: ALT: alanine aminotransferase. AST: aspartate aminotransferase. GGT: gamma glutamyl transpeptidase. HAART: highly active antiretroviral therapy. HCV: Hepatitis C virus. HCV-RNA: HCV plasma viral load. HIV-1: Human immunodeficiency virus type 1. HIV-RNA: HIV plasma viral load. NNRTI: non-nucleoside analogue HIV reverse transcriptase inhibitor. NRTI: nucleoside analogue HIV reverse transcriptase inhibitor. PI: protease inhibitor.